INmune Bio Statistics
Total Valuation
INmune Bio has a market cap or net worth of $178.17 million. The enterprise value is $157.63 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
INmune Bio has 22.93 million shares outstanding. The number of shares has increased by 10.92% in one year.
Current Share Class | 22.93M |
Shares Outstanding | 22.93M |
Shares Change (YoY) | +10.92% |
Shares Change (QoQ) | +10.21% |
Owned by Insiders (%) | 19.72% |
Owned by Institutions (%) | 27.24% |
Float | 14.93M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 12,726.32 |
Forward PS | n/a |
PB Ratio | 5.39 |
P/TBV Ratio | 11.43 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 11,259.32 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.
Current Ratio | 3.14 |
Quick Ratio | 3.09 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -54.04 |
Financial Efficiency
Return on equity (ROE) is -119.83% and return on invested capital (ROIC) is -65.75%.
Return on Equity (ROE) | -119.83% |
Return on Assets (ROA) | -55.19% |
Return on Invested Capital (ROIC) | -65.75% |
Return on Capital Employed (ROCE) | -131.83% |
Revenue Per Employee | $824 |
Profits Per Employee | -$2.48M |
Employee Count | 17 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.04% in the last 52 weeks. The beta is 1.88, so INmune Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.88 |
52-Week Price Change | -29.04% |
50-Day Moving Average | 8.44 |
200-Day Moving Average | 6.80 |
Relative Strength Index (RSI) | 47.77 |
Average Volume (20 Days) | 262,905 |
Short Selling Information
The latest short interest is 5.58 million, so 24.31% of the outstanding shares have been sold short.
Short Interest | 5.58M |
Short Previous Month | 5.42M |
Short % of Shares Out | 24.31% |
Short % of Float | 37.34% |
Short Ratio (days to cover) | 22.60 |
Income Statement
In the last 12 months, INmune Bio had revenue of $14,000 and -$42.08 million in losses. Loss per share was -$2.11.
Revenue | 14,000 |
Gross Profit | 14,000 |
Operating Income | -42.64M |
Pretax Income | -37.74M |
Net Income | -42.08M |
EBITDA | n/a |
EBIT | -42.64M |
Loss Per Share | -$2.11 |
Full Income Statement Balance Sheet
The company has $20.92 million in cash and $384,000 in debt, giving a net cash position of $20.54 million or $0.90 per share.
Cash & Cash Equivalents | 20.92M |
Total Debt | 384,000 |
Net Cash | 20.54M |
Net Cash Per Share | $0.90 |
Equity (Book Value) | 32.10M |
Book Value Per Share | 1.44 |
Working Capital | 15.44M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -33.36M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | 100.00% |
Operating Margin | -304,535.71% |
Pretax Margin | -300,585.71% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
INmune Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.92% |
Shareholder Yield | -10.92% |
Earnings Yield | -23.62% |
FCF Yield | n/a |
Analyst Forecast
The average price target for INmune Bio is $24.33, which is 213.13% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $24.33 |
Price Target Difference | 213.13% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Revenue Growth Forecast (5Y) | 534.13% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
INmune Bio has an Altman Z-Score of 4.46 and a Piotroski F-Score of 2.
Altman Z-Score | 4.46 |
Piotroski F-Score | 2 |